Project Grant R35CA293978
Award Date
9/1/24
Completion Date
8/31/31
Dollars Obligated
$942K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $872,555 Cooperative Agreement under the Cancer Biology Research (CFDA 93.396) program to the Dana-Farber Cancer Institute, Inc. (DFCI) to enhance and further develop informatics methods for long-read cancer sequencing. The key objectives are to: 1) Improve existing methods for long-read analysis, including long-read alignment, assembly, and downstream bioinformatic tools for somatic variant discovery; 2) Generate a resource of long-read cancer...
The National Cancer Institute (NCI) awarded a $581,381.00 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research. The grant, with a period of performance from June 2025 to May 2030, will support research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. Specifically, the research aims to better understand DNA damage repair pathways and how they can...
This $330,543.28 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, was awarded under the Cancer Research Manpower federal grant program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. for the period of August 16, 2021 through March 31, 2022. The grant funds research aimed at developing a pan-cancer atlas of driver mutations in over 100,000 patients through a hypothesis-driven combined computational and experimental approach....
The National Cancer Institute (NCI) awarded a $170,640 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant will fund research to investigate the role of the histone demethylase KDM4C in driving tumor growth in triple-negative breast cancer. The project aims to determine if KDM4C prevents the proteolytic cleavage of the N-terminal tail of histone H3 by the enzyme cathepsin L, and whether this...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research in New York. The grant will fund research to determine the role of key proteins like RAD52, HELQ, and POLQ in backup DNA double-strand break repair pathways in homologous recombination deficient (HRD) cancers. The project aims to discover additional proteins involved in these alternative repair mechanisms...
The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $541,682 Project Grant to The Trustees of Columbia University in the City of New York, Health Sciences Division, for the project "Maintenance of Genome Stability in 3D - Cancer Cells". The project, running from July 3, 2024 to June 30, 2029, aims to better understand the mechanisms responsible for assembling DNA repair domains in cancer cells and evaluate the...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will provide $720,252 to the Dana-Farber Cancer Institute (DFCI) from April 1, 2025 to March 31, 2030 to characterize the genetic risk of cancer across diverse populations. The key products and services to be delivered include: Identifying chromatin quantitative trait loci (cQTLs) that confer risk of prostate cancer in men of African ancestry by...
The National Cancer Institute (NCI), through the Cancer Cause and Prevention Research (CFDA 93.393) program, awarded a $551,848 project grant to the Dana-Farber Cancer Institute (DFCI) in Boston, MA. The 5-year grant (9/1/2024 - 8/31/2029) will support research to investigate the molecular mechanisms by which the transcription factor SOX9 impairs differentiation and promotes developmental reprogramming in colorectal cancer (CRC) cells. The project aims to leverage mouse models, single-cell...
The National Cancer Institute (NCI) awarded a 5-year, $2,186,372 Project Grant under the CFDA 93.396 Cancer Biology Research program to the University of California, Irvine (UC Irvine). The grant will fund a multi-project program to address fundamental questions about the processes driving cancer initiation and progression. Three interdisciplinary research projects will leverage mouse models of chronic myeloid leukemia, melanoma, and BRCA1-driven triple-negative breast cancer to investigate...